^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

Published date:
04/27/2022
Excerpt:
First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01)….BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1016/j.jtho.2022.04.008